This Month in JAAD: October 2021

In the October 2021 issue of JAAD, King et al. present findings from a randomized controlled study evaluating the efficacy of oral baricitinib in treating adults with alopecia areata. The study involved 110 patients who were assigned to receive either a placebo or baricitinib at doses of 1 mg, 2 mg, or 4 mg daily. Results showed that a significantly higher proportion of patients achieved a Severity of Alopecia Tool score of ≤20 in the baricitinib 2 mg (33.3%, P = .016) and 4 mg (51.9%, P = .001) groups compared to the placebo group (3.6%). These findings support the efficacy and safety of baricitinib for patients experiencing ≥50% scalp hair loss.